CBSE Class 12th Result 2026: The Central Board of Secondary Education (CBSE) has addressed the growing concerns regarding the Class 12 evaluation process. After the viral reports claiming technical ...

CBSE Class 12 Result Date: Over 18 lakh students - including around 10.2 lakh boys and 8.3 lakh girls - are eagerly awaiting their Class 12 results. The Central Board of Secondary Education (CBSE) is ...

CBSE 12th Result 2026 Live: Class 12 results will be announced and available on the official websites. Follow the blog for latest updates on results, direct link and more. CBSE 12th Result 2026 Live: ...

CBSE has strongly denied recent media reports alleging technical glitches and delays in the evaluation of Class 12 answer sheets under its newly introduced On-Screen Marking (OSM) system. The board ...

With a few chemical tweaks and some dutiful protein partners, a new biotech from Flagship Pioneering thinks it has cracked the code to turn DNA into a brand-new class of therapeutics. The ...

Safety Jaquan Brisker, left, and cornerback Kyler Gordon were the first two draft picks of the Ryan Poles era in Chicago. Gordon is one of three players from the Bears' 2022 draft class to earn a ...

Biopharma companies appear to be more willing to go public after a long drought. Just this week, GLP-1 developer Kailera Therapeutics and proteomics company Alamar Biosciences launched IPO roadshows ...

Marc Cummings, president and CEO of Life Science Washington, speaking at a one-day forum focused on AI-driven biotech that was held in Seattle in October 2025. (Life Science Washington Photo) Seattle ...

The Kansas City Chiefs’ 2022 NFL Draft class has long been considered one of the most impactful in franchise history. The group helped shape the team’s modern dynasty and played a key role in multiple ...

Redmile Group added 695,000 shares of Immunome last quarter; the estimated trade size was $12.20 million based on average prices for the quarter. The quarter-end position value increased by $64.01 ...

Moderna (MRNA) gained 37% YTD through February 12th, making it the 12th-best performing stock in the S&P 500. The company reduced annual operating expenses by $2B. The FDA rejected Moderna’s flu ...